For over 40 years, the development of renal transplants and bone marrow transplants, the phenotyping of autoimmune diseases and genetic diseases, allowed most of the major medical advances of today. The major asset of the Institute Necker-Enfants Malades comes from the plurality of skills, the freedom and creativity of its researchers, their desire to diversify their research topics.

Translational activities will be pursued and promoted as much as possible. Indeed, this group of PIs has filed 24 patents, 4 of which are licenced to pharmaceutical companies. 13 R&D contracts have been signed with industry and 3 start-up companies incorporated with one of the above PIs as founder. To further strengthen the link with the socio-economic world, we intend to devote one floor of our research building to hosting private entities, either small companies or teams from bigger pharmaceutical industries wishing to collaborate with groups of the Necker-Enfants Malades Institute.

• Understanding the molecular mechanisms of leukemia is to use targeted therapies and avoid chemotherapy whose collateral damage is known
• Defeating diabetes, especially the type 1 in children (440,000 in the world), is to address the treatment of autoimmune diseases, more and more frequent in developed countries, as the case for multiple sclerosis or lupus.
• Succeed one day to control the immune system, thanks to the long experience and considerable clinical material at the Necker hospital on kidney and bone marrow transplantations, is a priority
• Seek to determine the mechanisms responsible for bacterial meningitis, debilitating in a few hours a perfectly healthy child or subject, is essential to develop effective and safe vaccines.
• Apply our knowledge of metabolism and growth to promote innovative and personalized therapies in the field of kidney disease, diabetes, cystic fibrosis, muscular dystrophy and various solid tumors.